News Sentiment

COCH sentiment intelligence

Envoy Medical Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 0.70 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+2.7% over one week, +10.7% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Abbott stock trades steady as diagnostics and medical devices underpin earnings momentum

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 2.7% Price confirming higher
Trend fit Trend active 10.7% over four weeks
Fair value -69.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 28
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
TMX Newsfile 8
Stock Titan 7
Investing.com 3
Ad-hoc-news.de 2
TradingView 2
StockStory 2
Benzinga 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 18
Regulatory and legal 7
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Stock Titan Direct company coverage

All 56 patients reach 3 months in Envoy Medical's hearing implant trial

Envoy Medical (NASDAQ: COCH) announced that all 56 patients in its pivotal clinical trial for the investigational Acclaim cochlear implant have completed their three-month visit milestone. This achievement is a crucial step toward the company's planned Premarket Approval (PMA) su

Tone
Positive 74/100
Event
Regulatory and legal
Published
21 Jul 2026 13:41
Source
Stock Titan
TMX Newsfile Direct company coverage

Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

Envoy Medical Inc. announced that all 56 patients in its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant have surpassed the three-month visit milestone. This achievement brings the company closer to submitting its Premarket Approval applic

Tone
Positive 73/100
Event
Regulatory and legal
Published
21 Jul 2026 13:41
Source
TMX Newsfile
Sahm Direct company coverage

EXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial Results

Envoy Medical Inc. reported improved 12-month results from Stage 1 of its pivotal clinical trial for the Acclaim cochlear implant, showing a significant increase in hearing performance compared to baseline and six-month data. Participants achieved a mean CNC word recognition scor

Tone
Positive 70/100
Event
Earnings
Published
16 Jul 2026 03:41
Source
Sahm
Investing.com South Africa Direct company coverage

H.C. Wainwright reiterates Envoy Medical stock rating on trial progress By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $2.50 price target for Envoy Medical (NASDAQ:COCH) after an update on the pivotal trial of its Acclaim cochlear implant. The company announced that the first three patients have completed their 12-month endpoint visits, with topli

Tone
Positive 75/100
Event
Analyst action
Published
15 Jul 2026 15:40
Source
Investing.com South Africa
Market source Direct company coverage

Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant

Envoy Medical announced positive 12-month data from Stage 1 of its pivotal clinical trial for the Acclaim® fully implanted cochlear implant, showing significant improvements in speech perception. The study's first 10 participants demonstrated a substantial increase in CNC word re

Tone
Positive 86/100
Event
Market update
Published
15 Jul 2026 04:40
Source
Market source
Investing.com Direct company coverage

Envoy Medical submits first module of PMA to FDA for implant

Envoy Medical Inc. (NASDAQ:COCH) has submitted the first module of its Modular Premarket Approval (PMA) application to the FDA for its Acclaim cochlear implant, which has Breakthrough Device Designation. The company plans to submit a total of four modules, with clinical data expe

Tone
Positive 66/100
Event
Regulatory and legal
Published
01 Jul 2026 12:10
Source
Investing.com
Stock Titan Direct company coverage

Envoy Medical starts FDA review of its breakthrough hearing device

Envoy Medical (NASDAQ: COCH) has submitted the first module of its modular Premarket Approval (PMA) application to the FDA for its Breakthrough Device-designated Acclaim cochlear implant. This marks the initial step in a four-module strategy, with the final clinical module expect

Tone
Positive 74/100
Event
Regulatory and legal
Published
01 Jul 2026 00:12
Source
Stock Titan
Stock Titan Direct company coverage

Envoy Medical (NASDAQ: COCH) terminates $15 million ATM equity facility

Envoy Medical, Inc. (NASDAQ: COCH) has terminated its $15 million at-the-market (ATM) equity facility, effective June 24, 2026. This decision, which also ends the related At The Market Offering Agreement, reflects the company's confidence in its current capital position. The comp

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 20:10
Source
Stock Titan
TMX Newsfile Direct company coverage

Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device

Envoy Medical Inc. has submitted the first module of its Modular Premarket Approval (PMA) application to the FDA for its Breakthrough Device-designated hearing solution. This modular approach allows for earlier FDA engagement and feedback, reducing regulatory risk and providing c

Tone
Positive 70/100
Event
Regulatory and legal
Published
30 Jun 2026 08:30
Source
TMX Newsfile
Simply Wall Street Direct company coverage

Envoy Medical (Nasdaq:COCH) - Stock Analysis

Envoy Medical (Nasdaq:COCH) is a hearing health company with a market cap of US$60.9m. The company faces significant risks including shareholder dilution, declining earnings, low revenue, negative equity, and issues with Nasdaq's listing requirements. Despite some positive earnin

Tone
Negative 18/100
Event
Earnings
Published
29 Jun 2026 22:40
Source
Simply Wall Street
Investing.com Direct company coverage

Envoy Medical terminates $15 million equity offering facility

Envoy Medical Inc. (NASDAQ:COCH) has terminated its at-the-market equity facility, which allowed it to sell up to $15 million in common stock, effective June 24, 2026. The company’s shares are currently trading at $0.63, a 56% decrease over the past year, with a market cap of $48

Tone
Negative 32/100
Event
Market update
Published
28 Jun 2026 14:11
Source
Investing.com
Investing.com UK Direct company coverage

Form 4 Envoy Medical Inc For: 23 June By Investing.com

This article announces the filing of a Form 4 by Envoy Medical Inc. for June 23rd. Form 4 is a U.S. Securities and Exchange Commission (SEC) document that must be filed by company insiders to report changes in their beneficial ownership of the company's securities. The brief noti

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 23:40
Source
Investing.com UK
TMX Newsfile Direct company coverage

Envoy Medical Terminates At-the-Market (ATM) Equity Facility

Envoy Medical, Inc. (NASDAQ: COCH) has announced the formal termination of its at-the-market (ATM) equity facility, effective June 24, 2026. This decision reflects the company's confidence in its current capital position. Envoy Medical focuses on pioneering fully implanted hearin

Tone
Positive 65/100
Event
Market update
Published
26 Jun 2026 10:39
Source
TMX Newsfile
TradingView Direct company coverage

Envoy Medical, Inc. Class A Actuals & Estimates (BOATS:COCH)

This article provides financial actuals and estimates for Envoy Medical, Inc. (BOATS:COCH). It details the company's income statement, balance sheet, cash flow, and valuation metrics, while also addressing frequently asked questions about its stock performance, earnings, revenue,

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 21:10
Source
TradingView
Stock Titan Direct company coverage

Envoy Medical (NASDAQ: COCH) ties major CEO RSU grant to FDA approval

Envoy Medical (NASDAQ: COCH) has updated CEO Brent Lucas's compensation package, including a new base salary of $420,000 and a potential $105,000 cash bonus tied to strategic goals. A significant portion of this revised compensation involves equity awards: 1,000,000 stock options

Tone
Positive 63/100
Event
Regulatory and legal
Published
25 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Envoy Medical shuts down its $15M stock-sale facility

Envoy Medical (NASDAQ: COCH) has terminated its at-the-market (ATM) equity facility, which previously allowed the company to sell up to $15 million in common stock. The termination, effective June 24, 2026, reflects the company's confidence in its current capital position. Follow

Tone
Positive 67/100
Event
Market update
Published
25 Jun 2026 12:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Envoy Medical terminates $15 million equity offering facility By Investing.com

Envoy Medical, Inc. has terminated its $15 million at-the-market equity facility, effective June 24, 2026. This facility allowed the company to offer and sell shares of its common stock. Despite the termination, the company, which develops fully implanted hearing solutions, conti

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 12:41
Source
Investing.com Canada
TradingView Direct company coverage

Envoy Medical, Inc. Class A Financial Disclosures & SEC Filings

This article provides an overview of Envoy Medical, Inc. Class A's financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It lists earnings reports from Q1 FY2025 to Q1 FY2026, highlighting key operational updates, clinical trial progress, and financial perfo

Tone
Positive 66/100
Event
Earnings
Published
13 Jun 2026 00:39
Source
TradingView